Melanoma – Natural History and Principles of Treatment

Slides:



Advertisements
Similar presentations
MELANOMA.
Advertisements

Should BRAF inhibitors be continued ‘beyond progression’? Is there a rationale for discontinuous dosing of BRAF inhibitors? Is there a rationale for alternation.
Staging. Treatment by Stage For early stage lung cancers, surgery or radiation alone For larger tumors (>4 cm) and N+, chemotherapy should be added.
Sentinel Lymph Node Biopsy in Melanoma
Matthew Kilmurry, M.D. St. Mary’s General Hospital Grand River Hospital.
Cases on 1st line use of Ipilimumab in BRAF+ patients, sequencing of therapies Erika Richtig.
Maša Radeljak Mentor: A. Žmegač Horvat
Clinical Cancer Research Theresa Higgins Cancer Center Beth Israel Deaconess Medical Center Boston, MA.
Breast Cancer 101 Barbara Lee Bass, MD, FACS Professor of Surgery
By Denae Bush.   1.The disease caused by an uncontrolled division of abnormal cells in a part of the body.  2.A malignant growth or tumor resulting.
Genomics Lecture 7 By Ms. Shumaila Azam. Tumor Tumor – abnormal proliferation of cells that results from uncontrolled, abnormal cell division A tumor.
Adjuvant therapy for renal cell carcinoma Dr.Mina Tajvidi oncologist.
Colorectal cancer Khayal AlKhayal MD,FRCSC
History 79 year old white male who came to the ER after a fall also had one week history of weakness, dry cough and chest congestion without any fever.
Selezione dei pazienti affetti da melanoma Vanna Chiarion Sileni Melanoma and Skin Cancer Unit IOV-IRCCS, Padova.
Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS , ONO-4538) and ipilimumab (IPI) concurrent.
Skin Cancer Carlos Garcia MD Dermatology at OUHSC No conflicts of interest to disclose.
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation 1 Phase III Randomized, Open-Label, Multicenter Trial (BRIM3) Comparing BRAF Inhibitor.
Cory Klinger Korey Kainec Ian Behra. What is Melanoma?? Melanoma is a malignant tumor. If not found early, melanoma can ne very dangerous. It is responsible.
SYSTEMIC THERAPY FOR UNRESECTABLE STAGE III OR METASTATIC CUTANEOUS MELANOMA Sarkheil Mehdi Hematologist- oncologist.
Casey Bower. What is Melanoma? Melanoma is the most common cancer in the United States and the most dangerous form of skin cancer, melanoma begins in.
Melanoma Olivia Wilson.
S KIN C ANCER By: Amanda Chahulski and Amanda Hall.
Melanoma Hai Ho, M.D. Department of Family Practice.
CANCER. THE WORD CANCER  FEAR  DEATH  PAIN  SUFFERING  LOSS  ECONOMIC LOSS  DISFIGUREMENT  WHAT’S THE FUTURE.
Update on 18 F-Fluorodeoxyglucose/Positron Emission Tomography and Positron Emission Tomography/ Computed Tomography Imaging of Squamous Head and Neck.
CANCER By: Amanda Herrod.
Cancer notes.
Terminology of Neoplasms and Tumors  Neoplasm - new growth  Tumor - swelling or neoplasm  Leukemia - malignant disease of bone marrow  Hematoma -
 Determining the Nature of a Breast Abnormality  It is a procedure that may be used to determine whether a lump is a cyst (sac containing fluid) or a.
New Developments in Cancer Treatment Dulcinea Quintana, MD.
In the name of God Isfahan medical school Shahnaz Aram MD.
 Identify different options of cancer therapy.  Most cancers are treated with a combination of approaches.
WHAT ARE THE RISK FACTORS FOR LUNG CANCER? SMOKING.
Cancer By: Erionne. What is Cancer Cancer begins in your cells, which are the building blocks of your body. Normally, your body forms new cells as you.
S KIN C ANCER Kathy Sheriff, RN, BSN. S KIN C ANCER One in five Americans Crucial risk factor—over exposure to UV radiation in sunlight Other cases, frequent.
Patient  64 yo caucasian woman noted to have elevated LFTs on annual P.E. Felt well.  US Liver: 9 cm mass in right lobe of liver  Biopsy: Melanoma,
Phase I Study of PLX4032: Proof of Concept for V600E BRAF Mutation as a Therapeutic Target in Human Cancer Flaherty K et al. American Society of Clinical.
Basal Cell Carcinoma. Basal Cell Carcinoma Basal Cell Carcinoma.
Cell Division Gone Wrong…. Cancer. Rates of Cell Division Inner lining of small intestine – a week or less Pancreas – a year or more Liver – Cell rarely.
Two Year Estimate of Overall Survival in COMBI-v, a Randomized, Open-Label, Phase 3 Study Comparing the Combination of Dabrafenib and Trametinib With Vemurafenib.
Cell Division Gone Wrong….
Cancer Basics EQ: What does cancer have to do with the cell cycle?
欢 迎 光 临欢 迎 光 临. NCCN Clinical Practice Guidelines in Oncology™ Melanoma Lili Yun nan biotherapy center
Conflict of Interest Declaration: Nothing to Disclose Presenter: Sophie Lamoureux Title of Presentation: A Comparison of Stereotactic Body Radiotherapy.
Hodgkin’s Lymphoma Hodgkin’s Lymphoma Disease in which malignant (cancer) cells form in the lymph system Type of cancer that develops in.
It is essential to obtain the exact history of the hypersalivation as well as a thorough and complete past medical history. Oral evaluation should be performed,
Treatment for Cancer. Surgery Treatment and prognosis depend on severity and spread of the cancer Treatment and prognosis depend on severity and spread.
YOUR CANCER TREATMENT: WHAT TO EXPECT FROM THE LATEST ADVANCEMENTS MIRIAM J. ATKINS, M.D.
Melanoma Raising Awareness. Quick Facts About 68,720 people were diagnosed with melanoma in ,650 died of melanoma Melanoma accounts for 3% of skin.
What should patients with BRAF mutant melanoma receive as front line therapy? Antoni Ribas, M.D. Professor of Medicine Professor of Surgery Professor of.
MALIGNANT MELANOMA. Outline Introduction Aetiology Types Invasion and Metastasis Risk Factors Diagnosis and Staging Treatment and Prevention.
Treatment for Cancer. Surgery Treatment and prognosis depend on severity and spread of the cancer Treatment and prognosis depend on severity and spread.
Melanoma Nati Lerman MD Division of Hematology/Medical Oncology MD Anderson Cancer Center at Cooper September 2016.
“Know the Skin You’re In”
Melanoma Staging an update
CCO Independent Conference Highlights
Pembrolizumab Drugbank ID :DB09037 Half life : 28 days.
Cervical Cancer Tiffany Smith HCP 102.
Melanoma - Skin Cancer Cancer Project.
COMPLICATIONS OF IMMUNOTHERAPY IN THE HOSPITALIZED PATIENT Vivek Batra MD, Emma Weaver MD Division of Medical Oncology, Thomas Jefferson University, Philadelphia.
Mucosal Melanoma Samantha Hauff.
Program Goals Introduction Case 1: A 44-Year-Old Woman.
Leukemia.
Treatment Overview: The Multidisciplinary Team
Nat. Rev. Clin. Oncol. doi: /nrclinonc
Statistics (from the National Institutes of Health)
Adjuvant Therapy in Melanoma
Malignant Melanoma Aalayis Suggs.
General strategies of Cancer Treatment and evaluation of Response
Presentation transcript:

Melanoma – Natural History and Principles of Treatment Melanoma Patient Symposium YNHH – Smilow Cancer Hospital Sept 11, 2014

What is Melanoma? Cancer of cells which are responsible for all types of body pigmentation (melanocytes) Melanocytes are primarily present in skin but are also present in the eye and mucous membranes (head sinuses, oral cavity, rectum/anus, vulva/vagina) Some types of melanoma are related to sun exposure and sunburns Malignant cells gain special properties through genetic (mutations) and other cell changes Uncontrolled growth Ability to travel in blood and lymphatics to other organs Can implant in other organs and divide and grow (metastases) Can remain dormant for years before growth is triggered Dormant state cannot be detected by scans or other tests

A - asymmetry B – borders irregular C – color variation D - diameter E- evolution F – funny looking 3

Skin Ocular Nasal Vulvar Anorectal Acral-lentiginous 4

? Primary Tumor Skin Mucosa Ocular Biology of Dormancy Not Understood Local (Lymphatic) Dissemination Local recurrence In-transit metastases Regional node involvement Hematogenous Dissemination Skin Lung Lymph node Liver Bone GI/mesentery CNS (+ leptomeninges) ? years

25-30% at presentation of systemic mets, 60-70% of all patients subsequently

Treatment of Primary Melanoma Excisional biopsy by dermatologist Greater than 90% present without distant metastases Referral to surgeon Wide local excision – margins ≥ 2cm for lesions > 1mm thick Sentinel Node Biopsy in regional basin For lesions > 0.75 thick For prognostic information – does not affect outcome In very high risk patients, CT scans or PET scans to rule out distant metastases Completion lymph node dissection (for positive SLNB)

What is my risk that distant metastases will be found in the future? The Three Important Questions After Complete Resection of Primary Melanoma (and Regional Nodes) What is my risk that distant metastases will be found in the future? What can be done to lower the risk that my cancer might recur? How will I be monitored to detect the cancer if it recurs?

Staging is Used to Provide Risk for Distant Recurrence (Distant Metastases) Risk Factors Depth of primary Ulceration under the microscope Presence of cancer cells in the regional nodes (from the sentinel node biopsy and complete lymph node dissection)

Prognostic Factors for Patients with Metastatic Disease

Principles of Monitoring for Recurrence No (good) data to understand the impact of frequency of type of monitoring on outcome Both determined by risk Views on monitoring may change as more effective therapies are introduced for advanced disease Evaluation by oncologist every 3 months to 1 year History, exam, blood work (CBC, liver function, LDH) CT scans and/or PET-CT scans in high risk individuals every 6 to 12 months Usually stop monitoring at 5-7 years Dermatology evaluation 2-4x yearly for detection of second primaries (10% risk)

Options to Reduce Recurrence Risk Observation Interferon-alfa Different dose and schedules Administration for up to one year Increases time to recurrence Reduces overall risk of recurrence by about 10% Can induce moderate to severe toxicity in some (fever, chills, fatigue, loss of appetite, depression, difficulty in concentration) Possible new options Ipilimumab (Yervoy) – not yet approved, data so far similar to interferon, potential for severe toxicity Clinical Trials – compare potential better agents to standard of care

Management of Advanced Disease Treat both the lesions seen on scans and areas of disease that have not yet appeared on scans Surgery, local injection, or radiation not sufficient to eliminate the disease Requires systemic (intravenous or oral) medications Use systemic therapies first that can induce long term remissions Control pain and manage lesions early that may cause early morbidity (pain, bleeding, limitation of function, unacceptable cosmetic appearance) Screen the brain at baseline and every 8-12 weeks CT scans of chest/abd/pelvis or CT chest + MRI abdomen/pelvis to ‘stage’ disease Repeat scans every 6-12 weeks (depends of treatment)

Options for systemic therapies Clinical Trials Immune therapies (can give long term remissions) High dose interleukin-2 (Proleukin) Ipilimumab (anti-CTLA-4) (Yervoy) Pembrolizumab (anti-PD-1) (Keytruda) Nivolumab (anti-PD-1) (Optiva) – approval pending Targeted therapies (rapid response in most but few have long term control) BRAF mutation– dabrafenib (dafinlar)/trametinib (mekinist), vemurafenib (zelboraf) NRAS mutation – investigation MEK + CDK4 inhibitors C-kit (mucosal and acral-lentiginous melanomas) – imatinib, dasatinib, sorafenib, others Cytotoxic Chemotherapy (can work rapidly but only in a few and rarely achieve long term control) Temozolomide (temodar) or dacarbazine Carboplatin and paclitaxel Biochemotherapy

Chemotherapy Biochemotherapy 2014 – Treatment Options for Metastatic Melanoma Targeted therapies Immune therapies mBRAF mNRAS mCKIT Interleukin-2 Vemurafenib CDK4i + MEKi cKITi Ipilimumab (anti-CTLA4) Dabrafenib Anti-PD1 (nivolumab) (pembrolizumab) Trametinib (MEKi) Nivolumab + ipilimumab Dabrafenib + Trametinib Vemurafenib + cometinib

Eligible for Immunotherapy yes GKS/SRS Brain mets Eligible for Immunotherapy yes C-kit mutation Ckit inhibitor No Mutation analyses Yes NRAS mutation CDK4i + MEKi PD NO mutation BRAF mutation Anti-PD1 Anti-CTLA-4 High dose IL-2 Adoptive Immunotherapy Other Investigational Immunotherapy Trials Yes Phase 1 Other targeted Rx Anti-angiogenesis Supportive care Chemotherapy BRAFi + MEKi BRAFi + other ERKi Yale Cancer Center Melanoma Treatment Algorithm

Il-2 Induced Regression of Melanoma Liver Metastases 6-24-05 11-23-05 Persistent/progressing disease in spleen, SQ buttock, and lung removed; NED x 7 years

Response to Ipilimumab 10 mg/kg x 2 doses 2 baseline brain mets regressed also: No disease progression 5+ years

Metastatic Melanoma, Anti-PD1 1 mg/kg every other week

Response to ipi/anti-PD1, 3/1 dose level

Response to ipi/anti-PD1, 3/1 dose level

Response to ipi/anti-PD1, 3/1 dose level

Cohort 8 response at 12 weeks

Overall Survival for Concurrent Therapy by Dose Cohort 100 90 80 70 60 50 40 30 20 10 2 Yr OS 79% Concurrent Cohorts 1-3 (n=53) 2 Yr OS 50% 1 Yr OS 94% 2 Yr OS 88% 1 Yr OS 85% Survival (%) 1 Yr OS 57% Censored Nivo 0.3 mg/kg + IPI 3 mg/kg (n=14) Nivo 1 mg/kg + IPI 3 mg/kg (n=17) Nivo 3 mg/kg + IPI 1 mg/kg (n=16) Nivo 3 mg/kg + IPI 3 mg/kg (n=6) 3 6 9 12 15 18 21 24 27 30 33 36 39 42 45 48 14 17 16 6 53 13 52 11 15 48 10 46 8 44 7 40 4 31 2 28 9 3 19 5 1 Pts at Risk Nivo 0.3_IPI 3 Nivo 1 _IPI 3 Nivo 3_IPI 1 Nivo 3_IPI 3 Concurrent Months Presented by: